Biogen Inc. (NASDAQ:BIIB)

Stock Price: $197.78

-2.84 (-1.42%)

Updated Sep 23, 2022 08:00 PM GMT+0000

Featured app

Invest now

68% of retail CFD accounts lose money

Overview

Financials

Statistics

Chart

Market Cap	28.70B
Revenue	10.63B
Gross Profit	8.22B
Shares Out	145.11M
EPS (ttm)	13.97
PE Ratio	13.9377
Forward PE	12.0023
Dividend Rate (ttm)	0.0000
Dividend Yield	0.0000

Trading Day	Sep 23
Last Price	$197.78
Previous Close	$200.62
Change ($)	-2.84
Change (%)	-1.42%
Day's Open	200.28
Day's Range	194.45 - 200.99
Day's Volume	1.44M
52 Week Range	187.16 - 291.54

About Biogen Inc.

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.

One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

News

Biogen tops Q2 2022 earnings and revenue estimates July 24, 2022

Biogen needs ‘this’ to unlock a 60% upside in its stock April 18, 2022

Biogen vs Eli Lilly: Jim Cramer weighs in January 12, 2022

Is it too late to sell Biogen stock after losing an appeal on its multiple sclerosis drug? November 30, 2021

Is it safe to buy Biogen stock after boosting guidance ahead of Street forecasts? October 20, 2021

Is Biogen stock a buy or sell as ALS study falls short of primary endpoints? October 18, 2021

Is Biogen stock a buy after Teva settled the Vumerity patent lawsuit? October 11, 2021

Should you buy SAVA stock in Q4 2021 amid positive Simufilam trial data? September 22, 2021

Eli Lilly shares edge higher despite Q2 earnings miss: should you buy or sell LLY? August 3, 2021

Biogen‘s Alzheimer treatment triggers debate regarding its real-world benefits July 22, 2021

Quick info

Country

United States

Industry

Biological Product (except Diagnostic) Manufacturing

Sector

Manufacturing

Employees

9,100

CEO

Michel Vounatsos

Address

225 Binney St
Cambridge
Massachusetts
02142-1031

Phone

17814642000

Website

www.biogen.com

Ticker Symbol

BIIB

Exchange

NASDAQ Stock Exchange

Reporting Currency

USD

Biogen Inc. earnings reports (2020)

	Q3 2020	Q2 2020	Q1 2020	Q1 2020
Actual EPS	8.84	10.26	9.14	9.14
Consensus EPS	8.09	8.02	7.72	7.72
Announce Time	BTO	BTO	BTO	BTO
Number of Estimates	29	27	27	27
EPS Surprise Dollar	0.75	2.24	1.42	1.42
EPS Report Date	21-10-2020	22-07-2020	21-04-2020	21-04-2020
Fiscal End Date	30-09-2020	30-06-2020	30-03-2020	30-03-2020
Year Ago	9.17	9.15	6.98	6.98
Year Ago % Change	-3.6%	12.13%	30.95%	30.95%

Biogen Inc. earnings reports (2019)

	Q4 2019	Q3 2019	Q2 2019
Actual EPS	8.34	9.17	9.15
Consensus EPS	8.03	8.3	7.53
Announce Time	BTO	BTO	BTO
Number of Estimates	28	24	27
EPS Surprise Dollar	0.31	0.87	1.62
EPS Report Date	30-01-2020	21-10-2019	22-07-2019
Fiscal End Date	31-12-2019	29-09-2019	29-06-2019
Year Ago	6.99	7.4	5.8
Year Ago % Change	19.31%	23.92%	57.76%

Biogen Inc. income statements (2022) (USD)

	July 2022
Total Revenue	2.59B
Cost of Revenue	484M
Gross Profit	2.11B
Research & Development	528.60M
Selling General & Admin	572.60M
Operating Expense	1.65B
Operating Income	0.94B
Other Income Expense Net	-29.4M
EBIT	0.91B
Interest Income	53.20M
Pretax Income	1.28B
Income Tax	216.70M
Minority Interest	700K
Net Income	1.06B
Net Income Basic	1.06B

Biogen Inc. income statements (2021) (USD)

	October 2021
Total Revenue	2.78B
Cost of Revenue	511.80M
Gross Profit	2.27B
Research & Development	702.40M
Selling General & Admin	654.10M
Operating Expense	2B
Operating Income	778.40M
Other Income Expense Net	0
EBIT	779.50M
Interest Income	63.70M
Pretax Income	292.20M
Income Tax	-25.9M
Minority Interest	-11.1M
Net Income	329.20M
Net Income Basic	329.20M

Biogen Inc. income statements (2020) (USD)

	October 2020	September 2020	June 2020	March 2020	March 2020
Total Revenue	3.38B	3.12B	3.40B	3.16B	3.16B
Cost of Revenue	449.10M	563.90M	523.90M	561.20M	561.20M
Gross Profit	2.93B	2.56B	2.88B	2.60B	2.60B
Research & Development	1.14B	1.09B	596.30M	427.90M	427.90M
Selling General & Admin	573.10M	573.10M	541.10M	570.10M	570.10M
Operating Expense	2.32B	2.23B	1.66B	1.56B	1.56B
Operating Income	1.06B	892.50M	1.74B	1.60B	1.60B
Other Income Expense Net	0	65.30M	296.80M	101.90M	101.90M
EBIT	1.04B	892.50M	1.74B	1.60B	1.60B
Interest Income	50.30M	56.30M	56.60M	44.30M	44.30M
Pretax Income	0.94B	0.96B	2.04B	1.70B	1.70B
Income Tax	240.80M	240.80M	446.10M	292M	292M
Minority Interest	2.40M	2.40M	64.40M	-6.5M	-6.5M
Net Income	701.50M	701.50M	1.54B	1.40B	1.40B
Net Income Basic	701.50M	701.50M	1.54B	1.40B	1.40B

Biogen Inc. income statements (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Total Revenue	3.26B	3.17B	3.21B	3.08B
Cost of Revenue	560M	498M	546.40M	670.20M
Gross Profit	2.70B	2.67B	2.66B	2.41B
Research & Development	646.50M	540.40M	484.80M	563.70M
Selling General & Admin	664.90M	554.50M	587.60M	567.70M
Operating Expense	1.87B	1.59B	1.62B	1.80B
Operating Income	1.39B	1.58B	1.59B	1.28B
Other Income Expense Net	343.20M	201M	171.30M	581.10M
EBIT	1.39B	1.58B	1.59B	1.28B
Interest Income	46M	45.80M	47.70M	47.90M
Pretax Income	1.73B	1.78B	1.76B	1.86B
Income Tax	276.10M	211.30M	248.10M	422.50M
Minority Interest	0	0	0	0
Net Income	1.44B	1.55B	1.49B	1.41B
Net Income Basic	1.44B	1.55B	1.49B	1.41B

Biogen Inc. income statements (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Total Revenue	3.15B	3.09B	3B	2.82B
Cost of Revenue	565.80M	553.40M	528.40M	549.90M
Gross Profit	2.58B	2.54B	2.47B	2.27B
Research & Development	611.60M	507.90M	0.98B	496.70M
Selling General & Admin	580.20M	497.70M	516.20M	501.30M
Operating Expense	1.76B	1.56B	2.03B	1.55B
Operating Income	1.39B	1.53B	0.97B	1.27B
Other Income Expense Net	23.80M	282.60M	204.30M	226.30M
EBIT	1.39B	1.53B	0.97B	1.27B
Interest Income	49.40M	49M	51.70M	50.50M
Pretax Income	1.41B	1.81B	1.18B	1.49B
Income Tax	469.60M	369.80M	263.70M	322.50M
Minority Interest	-1.9M	-1.5M	48.40M	-1.7M
Net Income	0.95B	1.44B	866.60M	1.17B
Net Income Basic	0.95B	1.44B	866.60M	1.17B

Biogen Inc. income statements (2017) (USD)

	December 2017	September 2017	June 2017
Total Revenue	3B	2.77B	2.73B
Cost of Revenue	617.80M	478.90M	483.70M
Gross Profit	2.39B	2.29B	2.24B
Research & Development	587.60M	446.40M	796.20M
Selling General & Admin	553.90M	433.80M	430.20M
Operating Expense	1.76B	1.36B	1.71B
Operating Income	1.24B	1.41B	1.02B
Other Income Expense Net	155M	197.50M	114.60M
EBIT	1.24B	1.41B	1.02B
Interest Income	56.80M	61.80M	63.60M
Pretax Income	1.40B	1.61B	1.13B
Income Tax	1.57B	383.80M	269.60M
Minority Interest	131.10M	0	0
Net Income	-297.4M	1.23B	862.80M
Net Income Basic	-297.4M	1.23B	862.80M

Biogen Inc. balance sheet (2022) (USD)

	July 2022
Current Cash	4.80B
Receivables	2B
Inventory	1.29B
Current Assets	9.74B
Other Current Assets	1.65B
Short Term Investments	1.65B
Long Term Investments	15.34B
Property/Plant Equipment	3.36B
Good Will	N.A
Intangible Assets	2.08B
Tangible Assets (Net)	4.05B
Other Assets	1.50B
Total Assets	25.08B
Accounts Payable	434.80M
Other Current Liabilities	3.58B
Total Current Liabilities	5.02B
Total Liabilities	13.21B
Long Term Debt	6.28B
Current Long Term Debt	1B
Minority Interest	-9.1M
Common Stock	145.90M
Treasury Stock	-2.98B
Retained Earnings	14.96B
Capital Surplus	N.A
Shareholder Equity	11.87B
Other Liabilities	N.A

Biogen Inc. balance sheet (2021) (USD)

	October 2021
Current Cash	2.96B
Receivables	2.12B
Inventory	1.35B
Current Assets	7.16B
Other Current Assets	736.30M
Short Term Investments	736.30M
Long Term Investments	16.64B
Property/Plant Equipment	3.41B
Good Will	N.A
Intangible Assets	2.29B
Tangible Assets (Net)	2.38B
Other Assets	2.02B
Total Assets	23.81B
Accounts Payable	427.90M
Other Current Liabilities	2.78B
Total Current Liabilities	4.21B
Total Liabilities	13.38B
Long Term Debt	6.27B
Current Long Term Debt	1B
Minority Interest	451.80M
Common Stock	148M
Treasury Stock	-2.98B
Retained Earnings	13.54B
Capital Surplus	N.A
Shareholder Equity	10.43B
Other Liabilities	N.A

Biogen Inc. balance sheet (2020) (USD)

	October 2020	September 2020	June 2020	March 2020	March 2020
Current Cash	3.58B	2.22B	2.38B	2.59B	2.59B
Receivables	2.55B	2.55B	2.57B	2.60B	2.60B
Inventory	1.03B	1.03B	0.95B	858.80M	858.80M
Current Assets	7.84B	7.84B	8.49B	8.01B	8.01B
Other Current Assets	683.50M	683.50M	638.80M	683.80M	683.80M
Short Term Investments	683.50M	1.36B	1.94B	1.27B	1.27B
Long Term Investments	17.09B	2.50B	2.29B	1.84B	1.84B
Property/Plant Equipment	3.36B	3.79B	3.77B	3.70B	3.70B
Good Will	N.A	N.A	N.A	N.A	N.A
Intangible Assets	3.32B	3.32B	3.38B	3.45B	3.45B
Tangible Assets (Net)	1.68B	-9.15B	-8.59B	-7.36B	-7.36B
Other Assets	1.83B	349.70M	116.90M	263.10M	263.10M
Total Assets	24.93B	24.93B	25.51B	26.12B	26.12B
Accounts Payable	398.40M	398.40M	383.90M	389M	389M
Other Current Liabilities	3.41B	3.29B	2.49B	2.44B	2.44B
Total Current Liabilities	3.80B	3.80B	3.45B	4.64B	4.64B
Total Liabilities	14.18B	14.19B	14.22B	13.58B	13.58B
Long Term Debt	7.43B	7.83B	7.84B	4.86B	4.86B
Current Long Term Debt	0	N.A	N.A	1.50B	1.50B
Minority Interest	-14M	2.40M	64.40M	-6.5M	-6.5M
Common Stock	100K	153.90M	158.30M	167.30M	167.30M
Treasury Stock	-2.98B	2.98B	2.98B	2.98B	2.98B
Retained Earnings	13.96B	13.96B	14.47B	15.67B	15.67B
Capital Surplus	N.A	N.A	N.A	100K	100K
Shareholder Equity	10.76B	10.76B	11.31B	12.55B	12.55B
Other Liabilities	N.A	N.A	N.A	N.A	N.A

Biogen Inc. balance sheet (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Current Cash	2.91B	2.34B	1.72B	2.24B
Receivables	2.47B	2.52B	2.52B	2.62B
Inventory	804.20M	751.80M	776.70M	770.20M
Current Assets	8.38B	8.45B	7.91B	8.94B
Other Current Assets	631M	743.20M	1.66B	1.65B
Short Term Investments	1.56B	2.09B	1.23B	1.67B
Long Term Investments	2.38B	2.22B	1.66B	2.33B
Property/Plant Equipment	3.67B	3.56B	3.51B	3.46B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	3.53B	3.39B	3.68B	3.06B
Tangible Assets (Net)	-6.58B	-5.7B	-6.97B	-5.18B
Other Assets	278.70M	836.80M	0.96B	0.94B
Total Assets	27.23B	27.48B	26.29B	26.45B
Accounts Payable	530.80M	382.20M	377.10M	378M
Other Current Liabilities	2.69B	2.36B	2.41B	2.53B
Total Current Liabilities	4.86B	4.43B	3.21B	3.15B
Total Liabilities	13.90B	13.49B	13.34B	12.62B
Long Term Debt	4.87B	4.87B	6.37B	6.38B
Current Long Term Debt	1.50B	1.50B	N.A	N.A
Minority Interest	0	0	0	0
Common Stock	174.20M	181.90M	184.80M	195.20M
Treasury Stock	2.98B	2.98B	2.98B	2.98B
Retained Earnings	16.46B	17.07B	16.18B	17.03B
Capital Surplus	N.A	N.A	N.A	N.A
Shareholder Equity	13.34B	14B	12.95B	13.83B
Other Liabilities	N.A	N.A	N.A	N.A

Biogen Inc. balance sheet (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Current Cash	1.22B	2.39B	1.25B	4.11B
Receivables	2.49B	2.53B	2.43B	2.49B
Inventory	0.93B	0.92B	0.93B	890.80M
Current Assets	7.64B	8.72B	7.43B	10.20B
Other Current Assets	687.60M	848.30M	843.30M	895.90M
Short Term Investments	2.31B	2.04B	1.97B	1.81B
Long Term Investments	2.73B	1.93B	1.71B	1.28B
Property/Plant Equipment	3.60B	3.54B	3.41B	3.33B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	3.12B	3.38B	3.66B	3.79B
Tangible Assets (Net)	-6.1B	-5.18B	-6.34B	-4.05B
Other Assets	333.70M	322M	353.10M	298.50M
Total Assets	25.29B	25.49B	23.95B	26.09B
Accounts Payable	370.50M	342.30M	295.70M	345.80M
Other Current Liabilities	2.86B	2.58B	2.63B	2.57B
Total Current Liabilities	3.30B	3.17B	3.15B	3.15B
Total Liabilities	12.26B	11.73B	11.70B	12.05B
Long Term Debt	5.94B	5.93B	5.93B	5.93B
Current Long Term Debt	N.A	N.A	N.A	3.30M
Minority Interest	-1.9M	-1.5M	48.40M	-1.7M
Common Stock	197.20M	201.48M	201.44M	211.01M
Treasury Stock	2.98B	2.98B	2.98B	2.98B
Retained Earnings	16.26B	16.94B	15.50B	17.33B
Capital Surplus	N.A	47.80M	N.A	N.A
Shareholder Equity	13.04B	13.77B	12.26B	14.05B
Other Liabilities	N.A	N.A	N.A	N.A

Biogen Inc. balance sheet (2017) (USD)

	December 2017	September 2017	June 2017
Current Cash	1.57B	1.55B	1.17B
Receivables	2.32B	2.09B	2.13B
Inventory	0.90B	1.01B	0.94B
Current Assets	7.87B	7.57B	7.11B
Other Current Assets	0.96B	0.97B	1.15B
Short Term Investments	2.12B	1.96B	1.72B
Long Term Investments	3.14B	3.15B	2.73B
Property/Plant Equipment	3.18B	3B	2.83B
Good Will	N.A	N.A	N.A
Intangible Assets	3.88B	4.02B	4.05B
Tangible Assets (Net)	-4.92B	-3.69B	-4.37B
Other Assets	0.94B	1.22B	1.17B
Total Assets	23.65B	23.07B	21.76B
Accounts Payable	395.50M	298.70M	330.30M
Other Current Liabilities	2.90B	2.46B	2.44B
Total Current Liabilities	3.37B	3.45B	3.38B
Total Liabilities	11.05B	10.22B	10.19B
Long Term Debt	5.94B	5.94B	5.95B
Current Long Term Debt	3.20M	573.20M	559.90M
Minority Interest	131.10M	0	0
Common Stock	211.50M	211.48M	211.43M
Treasury Stock	2.98B	2.98B	2.98B
Retained Earnings	15.81B	16.11B	14.88B
Capital Surplus	97.80M	59.20M	19.30M
Shareholder Equity	12.61B	12.86B	11.59B
Other Liabilities	N.A	N.A	N.A

Biogen Inc. cash flow (2022) (USD)

	July 2022
Net Income	1.06B
Depreciation	134.80M
Changes in Receivables	2B
Changes in Inventories	1.29B
Cash Change	4.80B
Cash Flow	736.50M
Capital Expenditures	-38.8M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	693.50M
Dividends Paid	N.A
Net Borrowings	834M
Other Financing Cash Flows	N.A
Cash Flow Financing	-471.5M
Exchange Rate Effect	N.A

Biogen Inc. cash flow (2021) (USD)

	October 2021
Net Income	329.20M
Depreciation	133.20M
Changes in Receivables	2.12B
Changes in Inventories	1.35B
Cash Change	2.96B
Cash Flow	805.30M
Capital Expenditures	-43.9M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-286.5M
Dividends Paid	N.A
Net Borrowings	3.58B
Other Financing Cash Flows	N.A
Cash Flow Financing	-746.5M
Exchange Rate Effect	N.A

Biogen Inc. cash flow (2020) (USD)

	October 2020	September 2020	June 2020	March 2020
Net Income	701.50M	701.50M	1.54B	1.40B
Depreciation	366.80M	114.70M	112.90M	119.90M
Changes in Receivables	-22.6M	22.60M	29.50M	-133.5M
Changes in Inventories	75M	-82.4M	-126M	-62.2M
Cash Change	-747.8M	-160.1M	-206.4M	-322.4M
Cash Flow	4.60B	1.18B	1.95B	1.47B
Capital Expenditures	-338.8M	-84.1M	-105M	-261.7M
Investments	N.A	41.90M	-720.4M	705.10M
Investing Activity (other)	N.A	-10.2M	-7.3M	-500K
Total Investing Cash Flows	-442.2M	-52.4M	-832.7M	442.90M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	3.16B	N.A	1.47B	N.A
Other Financing Cash Flows	N.A	-70.3M	17.80M	4.50M
Cash Flow Financing	-4.87B	-1.31B	-1.31B	-2.25B
Exchange Rate Effect	N.A	24.10M	-8.8M	12.70M

Biogen Inc. cash flow (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Net Income	1.44B	1.55B	1.49B	1.41B
Depreciation	-103M	329.50M	117M	121.10M
Changes in Receivables	45.10M	1.30M	98.90M	-130.6M
Changes in Inventories	-66.5M	-61.4M	-20.3M	129M
Cash Change	569.80M	620.50M	-520.6M	1.02B
Cash Flow	1.96B	1.69B	1.96B	1.46B
Capital Expenditures	-265.4M	-90.1M	-186.9M	-127.1M
Investments	0.94B	-1.2B	826.20M	664.20M
Investing Activity (other)	4.60M	-600K	-4M	-300M
Total Investing Cash Flows	708.40M	-365.9M	-110.8M	238.80M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	N.A	N.A	N.A	N.A
Other Financing Cash Flows	-40.2M	22.20M	17.20M	8.70M
Cash Flow Financing	-2.12B	-689M	-2.38B	-679.3M
Exchange Rate Effect	17.60M	-19.5M	1.90M	400K

Biogen Inc. cash flow (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Net Income	0.95B	1.44B	866.60M	1.17B
Depreciation	153M	157.20M	171.50M	168.90M
Changes in Receivables	40.30M	-92.8M	59.80M	-173.1M
Changes in Inventories	-20.2M	8.20M	-42.7M	2.60M
Cash Change	-1.16B	1.14B	-2.86B	2.53B
Cash Flow	1.90B	1.74B	1.10B	1.46B
Capital Expenditures	-225.9M	-190.7M	-264.8M	-204.7M
Investments	-1.56B	-127.5M	-121.3M	2.15B
Investing Activity (other)	162.90M	-299.2M	-763.7M	-600M
Total Investing Cash Flows	-1.63B	-619.1M	-1.15B	1.35B
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	N.A	N.A	-3.2M	N.A
Other Financing Cash Flows	-84.4M	25.10M	-38.3M	-18.6M
Cash Flow Financing	-1.44B	25.10M	-2.79B	-268.6M
Exchange Rate Effect	4.80M	-5.4M	-17.1M	-0.9M

Biogen Inc. cash flow (2017) (USD)

	December 2017	September 2017	June 2017
Net Income	-297.4M	1.23B	862.80M
Depreciation	177.80M	177.40M	182.60M
Changes in Receivables	-234.1M	47.60M	-307.1M
Changes in Inventories	75.80M	-85M	-39.1M
Cash Change	25.70M	378.60M	245.50M
Cash Flow	1.52B	1.63B	1.17B
Capital Expenditures	-175.6M	-279.2M	-322.8M
Investments	-168M	-669.8M	420.90M
Investing Activity (other)	-425.9M	-297.8M	-300.7M
Total Investing Cash Flows	-769.5M	-1.25B	-202.6M
Dividends Paid	N.A	N.A	N.A
Net Borrowings	-557.7M	-3.2M	N.A
Other Financing Cash Flows	-150.4M	-16.3M	30.80M
Cash Flow Financing	-708.1M	-19.5M	-751M
Exchange Rate Effect	-15M	16.60M	29.90M